

## Q-linea - A targeted AStar launch strategy

Q-linea is in the early stage of its targeted European launch strategy. The strong point is that Q-linea has developed a product ready for clinical use with positive initial feedback. The main go-to-market challenge is that it could take a bit longer to introduce AStar in Europe without an international partner. The European market will require supporting clinical studies, including positive peer-to-peer review, before accepting rapid AST as a larger part of the standard of care.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Q-linea - A targeted AStar launch strategy](#)